The Onco Life Podcast
Welcome to The Onco Life Podcast, your trusted source for cancer care insights, treatment updates, and patient-centered education. Hosted by the team at Onco Life Centre in Kuala Lumpur, Malaysia, this podcast is designed to guide patients, caregivers, and listeners through every stage of the cancer journey.
Each episode features expert advice from our oncologists, wellness tips, treatment innovations, and answers to the most common questions about cancer types, therapies, and recovery.
🎧 Empowering you with knowledge, support, and compassionate care—every step of the way.
📍 Kuala Lumpur, Malaysia
🌐 Learn more at oncolifecentre.com
The Onco Life Podcast
Genetic Testing for Breast Cancer: Who Should Get Tested and Why It Matters
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
In this episode, we explain how genetic testing can help identify inherited breast cancer risk and why it may be an important step for individuals and families with a history of cancer.
You’ll learn:
• What genetic testing is and how it helps assess breast cancer risk
• The role of BRCA1 and BRCA2 gene mutations in inherited cancer risk
• Who should consider genetic testing, including those with a strong family history of cancer
• Why breast cancer diagnosed before age 50 may be linked to inherited gene changes
• How ovarian cancer, pancreatic cancer, prostate cancer, and male breast cancer can signal a hereditary cancer risk
• Why people with Ashkenazi Jewish heritage may benefit from genetic screening
• What happens during the testing process and how genetic test results are interpreted
• How genetic testing can guide earlier screening, prevention planning, and family health decisions
• Common myths about BRCA testing and inherited cancer risk
Whether you're concerned about your family history or want to better understand your personal cancer risk, this episode provides a clear guide to genetic testing for breast cancer and how it can support informed healthcare decisions.
Blog Link: Genetic Testing for Breast Cancer: Who Should Get Tested?
Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education.
Author: Dr. CHRISTINA NG VAN TZE
📍 Visit us at oncolifecentre.com
📞 Call: +60 3 2242 3260
📧 Book a consultation or ask a question — we're here to support your journey.
Welcome to the Unco Life Center podcast.
SPEAKER_00Thanks for having me.
SPEAKER_01So right now, um, hiding in your saliva is this microscopic instruction manual. And it basically dictates how your body might behave 10, 20, or you know, even 30 years from now.
SPEAKER_00Yeah. And the crazy thing is, most of us just go our whole lives without ever reading it.
SPEAKER_01Right. I mean, we usually think of inheritance in terms of like the visible things. You look at an old family photograph and you try to spot uh who gave you your height or who passed down those blue eyes.
SPEAKER_00Exactly. Yeah. But stepping into the world of modern oncology and genetics, well, it means looking at this whole landscape of invisible inheritance.
SPEAKER_01Aaron Powell, which is exactly why we are doing this deep dive today. We are looking into a question that completely alters how you approach your long-term health, which is genetic testing for breast cancer.
SPEAKER_00Aaron Powell Yeah, we really need to figure out who should actually get tested and um what happens when those results come back. Because understanding that invisible inherited risk, it completely shifts you from playing defense to playing offense.
SPEAKER_01Oh, for sure.
SPEAKER_00If you are mapping out your own health future or, you know, looking out for your family, you want to move away from just guessing about your health based on who got sick in the past.
SPEAKER_01Aaron Ross Powell Right. You want to shift toward highly precise proactive data. You go from being reactive to anticipating vulnerabilities before they ever like have the chance to develop into a disease.
SPEAKER_00Exactly.
SPEAKER_01And our focus today is grounded in the clinical practices and resources from the Onko Life Center, which is located in Kuala Lumpur, Malaysia, specifically uh WISMA Life Care in Bangzar South.
SPEAKER_00Which is important because when you're talking about extracting data from someone's DNA to predict cancer risk, I mean credibility is everything.
SPEAKER_01Yeah, you want to understand the environment where this level of medicine is being practiced. And the materials from the center emphasize four core operating values, which are empathy, dedication, professionalism, and quality.
SPEAKER_00Right. And those principles dictate the entire patient experience there. I mean, the global footprint of this facility provides a lot of context for their standard of care.
SPEAKER_01They treat people from all over, right?
SPEAKER_00Oh, yeah. They are drawing patients from an incredibly wide geographical area. We're talking Germany, Iran, Qatar, Bangladesh.
SPEAKER_01Wow, that's a massive reach.
SPEAKER_00It really is. India, Indonesia, the Philippines, Singapore, China, Japan, the UK. So managing that diversity of patients, uh, it requires an infrastructure that operates at the absolute highest international standards.
SPEAKER_01Aaron Powell And that level of infrastructure really shows up in the technical details of their treatment facilities. Like in the source material, it mentions their chemotherapy service operates something called a CDR complex.
SPEAKER_00Yes, the cytotoxic drug reconstitution complex.
SPEAKER_01Aaron Powell Right. Which I gotta admit sounds intense, like almost like something out of a sci-fi movie or the military. What exactly are they reconstituting in there?
SPEAKER_00Aaron Powell Well, cytotoxic drugs are um they're the foundational medications used in chemotherapy. Their specific purpose is to destroy rapidly dividing cancer cells.
SPEAKER_01Okay, that makes sense.
SPEAKER_00But because they are so potent and well, toxic, they can't just be mixed on a standard pharmacy counter. They have to be handled and prepared or reconstituted with absolute precision.
SPEAKER_01Aaron Powell Right, to protect both the medication and the people handling it, I'm guessing.
SPEAKER_00Exactly. The CDR complex at the OncO Life Center is this state-of-the-art, highly controlled laboratory environment. It's actually certified by the National Pharmaceutical Regulatory Agency of Malaysia's Ministry of Health.
SPEAKER_01Oh, wow. So they don't mess around.
SPEAKER_00Not at all. Highly qualified pharmacy personnel prepare these intense drugs under incredibly strict standard operating protocols.
SPEAKER_01So the goal is ensuring the patient receives the exact right dose, completely uncompromised by the outside environment, while also, you know, making sure the pharmacy staff aren't accidentally exposed to toxic chemicals.
SPEAKER_00Yeah, that's the entire function of the complex. It requires specialized ventilation, clean room technology, and just really rigorous safety checks.
SPEAKER_01Which honestly, if a facility is investing that heavily in the absolute highest standard of safety and precision for the treatment side of cancer, it naturally reflects the rigor applied to the diagnostic and preventative side.
SPEAKER_00Aaron Powell Including genetic testing.
SPEAKER_01Right. So let's get into the mechanics of that prediction. The process of actually spotting a potential cancer risk before it happens is almost anticlimactic in its simplicity.
SPEAKER_00It really is.
SPEAKER_01I mean, it is literally just a blood draw or a saliva test. You spit in a tube or give a small vial of blood. But what the laboratory is looking for inside that sample is um it's profound.
SPEAKER_00They are searching for inherited genetic changes. And they're primarily focusing on the BRCA1 and BRCA2 genes.
SPEAKER_01Okay, so to understand why these specific genes are the focus of a cancer test, I think we have to look at what they do when they're functioning normally.
SPEAKER_00Right, because your body is constantly regenerating. Every single day, your cells divide and replicate.
SPEAKER_01And every time a cell divides, it has to copy roughly, what, three billion base pairs of DNA?
SPEAKER_00Yeah, something crazy like that. And in a process, that massive errors are inevitable.
SPEAKER_01So the way I like to think about it is imagine your body as a massive publishing house. It is printing billions of pages of cellular instruction manuals every single day.
SPEAKER_00That's a great analogy.
SPEAKER_01And the BRCA genes act as the spell check program in your body. When the spell check is working perfectly, it scans those billions of pages, catches any typos or errors in the DNA, and fixes them before the cell finishes replicating.
SPEAKER_00Exactly. The scientific term for them is tumor suppressor genes. Their literal biological job is to repair DNA damage.
SPEAKER_01But if the spell check itself has a mutation, like a glitch in its own code, it loses the ability to identify and fix those daily errors. Aaron Powell Right.
SPEAKER_00So the typos slip through. And what's fascinating here is that those uncorrected errors, they compound over time.
SPEAKER_01So the instructions just get more and more garbled.
SPEAKER_00Yeah. Until an abnormal cell is produced that ignores the body's standard commands to stop growing, which is essentially how cancer develops.
SPEAKER_01Wow. And that mechanism changes how we view the test results. Cause a mutation in the BRCA genes does not mean you have cancer, right?
SPEAKER_00No, not at all. It just means your body's natural daily defense mechanism against cellular errors is compromised. You are basically operating without the spell check.
SPEAKER_01But spotting that vulnerability is just the first step. The clinical guidance strongly emphasizes that raw genetic data is largely useless and honestly often terrifying without expert translation.
SPEAKER_00Oh, absolutely. The lab doesn't just like email you a PDF with a positive or negative check mark and leave you to figure it out.
SPEAKER_01That would be a nightmare.
SPEAKER_00It would. A genetic counselor or a specialized oncologist must review the findings with you. Their job is to contextualize the risk.
SPEAKER_01So they look at the specific type of mutation and combine it with your age, your lifestyle, and your physical health.
SPEAKER_00Yeah, and they translate that complex data into a real-world actionable prevention plan.
SPEAKER_01Which brings us to the most critical question of this deep dive. Who should actually be utilizing this tool? Right. If the test is as simple as providing a saliva sample and the stakes are avoiding cancer, I feel like the natural instinct is to think every single person should be tested immediately.
SPEAKER_00I get why people think that, but widespread indiscriminate testing of the general population often causes way more harm than good.
SPEAKER_01Really? How so?
SPEAKER_00Well, it can lead to false positives or the detection of genetic variants of unknown significance. And that just triggers a cascade of unnecessary anxiety and invasive medical procedures.
SPEAKER_01Ah, that makes sense. So the clinical approach is more targeted.
SPEAKER_00Exactly. We look for specific red flags that suggest a high probability of a genetic mutation driving the risk.
SPEAKER_01And Dr. Christina Nengvansi highlights a few very specific high-risk criteria in her article. One of the primary indicators is an early age breast cancer diagnosis, right?
SPEAKER_00Yes. If someone develops breast cancer in their twenties or thirties, the statistical likelihood shifts. It suggests that genetics, rather than just aging and environmental factors over decades, might be the primary driver of the disease.
SPEAKER_01Another critical factor is heritage. The guidelines specifically note individuals of Ashkenazi Jewish descent.
SPEAKER_00Right, due to the historical realities of closed populations and a smaller genetic pool over centuries, which is a concept known as the founder effect. Certain BRCA mutations are significantly more prevalent in this specific group.
SPEAKER_01Compared to the general population, yeah. And then the most well-known criterion is family history. Having multiple relatives diagnosed with cancer, particularly breast cancer before the age of 50, is a major red flag.
SPEAKER_00It is.
SPEAKER_01But looking closer at the specific family history recommendations, there's this fascinating connection. Testing isn't just recommended for families with a history of breast or ovarian cancer.
SPEAKER_00No, it's broader than that.
SPEAKER_01The protocols explicitly advise testing if there is a strong family history of pancreatic cancer or prostate cancer.
SPEAKER_00Wait, let's unpack this. How do prostate and pancreatic cancer connect to a test for breast cancer?
SPEAKER_01I know it seems counterintuitive to look at prostate cancer when assessing breast cancer risk. But this goes back to the mechanism of the spell check we talked about earlier.
SPEAKER_00Okay, right.
SPEAKER_01The BRCA gene's job is repairing DNA across the entire body. It is a systemic function. We colloquially call them the breast cancer genes, but they are actually systemic DNA repair genes. Oh. So the glitch in the spell check affects cells everywhere. The tissue in the breast and the ovaries just happen to be particularly susceptible to this specific type of DNA repair failure.
SPEAKER_00Exactly. The high cellular turnover and hormonal environment of breast and ovarian tissue make them highly vulnerable when the BRCA mechanism fails.
SPEAKER_01But that exact same genetic mutation also significantly increases the risk of pancreatic and prostate cancers.
SPEAKER_00Yes. The underlying vulnerability is identical.
SPEAKER_01So if you are like tracing your family tree and you notice an uncle who battled prostate cancer and a grandmother who passed away from pancreatic cancer, that is a massive neon sign.
SPEAKER_00Aaron Powell It really is. It points toward a potential BRCA mutation in the bloodline, even if there isn't a single case of breast cancer in the family history.
SPEAKER_01That is wild.
SPEAKER_00It represents a clear pattern of systemic DNA repair failure traversing the generations. And recognizing that pattern is crucial because it shatters several dangerous myths surrounding who is actually at risk.
SPEAKER_01Yeah, that prostate cancer connection naturally forces us to confront the single biggest misconception about genetic testing. Society conditions us to view breast cancer as an exclusively female issue.
SPEAKER_00Which is just not true. The science clearly dictates that men are an equal half of the genetic equation.
SPEAKER_01Men can carry the BRCA mutation, they can pass it on, and they can be directly affected by it. I mean, male breast cancer is a known, documented reality, and it's closely tied to these inherited genetic mutations.
SPEAKER_00Right. The anatomical risk is lower simply because men have less breast tissue, but the underlying genetic vulnerability is exactly the same.
SPEAKER_01And beyond their own risk of developing cancer, the inheritance factor is just critical. A father carrying the BRCA mutation has a 50% chance of passing it to his children.
SPEAKER_00Exactly. A father passing this risk to his daughter is just as likely as a mother passing it to her daughter.
SPEAKER_01But this represents a massive breakdown in medical communication within families, doesn't it?
SPEAKER_00Oh, huge. Families often entirely discount the paternal side of the family tree when assessing breast cancer risk.
SPEAKER_01Right. So a daughter might look at her mother's flawless health history and assume she's completely safe, totally unaware that her father carries a BRCA mutation and passed it to her.
SPEAKER_00Yep. Men must realize their family medical history is just as relevant to their daughter's breast health as the mother's history.
SPEAKER_01That leads directly into another major psychological barrier to testing. People often rely on a clean family tree as a shield.
SPEAKER_00Oh, all the time.
SPEAKER_01They look back two or three generations, see no obvious cancer diagnoses, and assume they have zero inherited risk.
SPEAKER_00But assuming a clean family tree means zero risk relies on the assumption of perfect information. And in reality, family histories are incredibly messy and full of holes. Yeah. A family might be exceptionally small, meaning there simply aren't enough relatives for the statistical risk to materialize in a noticeable pattern.
SPEAKER_01Or the information was intentionally buried. I mean, go back a generation or two, and there was massive societal stigma surrounding cancer.
SPEAKER_00Especially cancers of the reproductive system.
SPEAKER_01Right. A great grandmother might have passed away from ovarian cancer, but in her era, it was whispered about as women's troubles and never officially spoken of again.
SPEAKER_00Exactly. Generational secrets, lost medical records, and misdiagnoses all create a false sense of security. An absence of information is not an absence of risk.
SPEAKER_01So if you have an early age diagnosis yourself, or if you belong to a high-risk heritage group, pursuing a genetic test is often warranted, regardless of how clean the visible family tree appears.
SPEAKER_00Absolutely.
SPEAKER_01Then there's the fear of the result itself. I feel like the hesitation to get tested often stems from the belief that a positive test is a guaranteed cancer diagnosis. It feels like taking a test just to find out when the clock is going to run out.
SPEAKER_00And that's why we have to firmly separate genetic risk from biological certainty. Receiving a positive result means your spell checker has a glitch.
SPEAKER_01Okay.
SPEAKER_00It means you possess a higher baseline risk compared to the general population. It absolutely does not guarantee that you will ever develop cancer.
SPEAKER_01Right. Cause countless individuals with known DRCA mutations live long, entirely healthy lives without the disease ever manifesting.
SPEAKER_00Exactly. And the reverse is equally true. A negative result doesn't grant you invincibility.
SPEAKER_01A negative test simply means you do not carry the specific inherited vulnerability.
SPEAKER_00Right. But the vast majority of breast cancers are not hereditary. Environmental factors, lifestyle choices, hormonal changes, and the simple process of aging still play massive roles in disease development.
SPEAKER_01So a negative test isn't a free pass to skip screenings, and a positive test isn't a terminal diagnosis.
SPEAKER_00Perfectly said.
SPEAKER_01So when a patient receives that positive result, the focus immediately shifts from diagnosis to action. This is where the tactical roadmap is built. The clinical teams at facilities like Onco Life Center implement a very specific blueprint for prevention.
SPEAKER_00Yeah, the first step is fundamentally altering the screening timeline. You don't wait for the standard recommended age of 40 or 50 to begin preventative checks.
SPEAKER_01Screenings start much earlier, often in the patient's 20s.
SPEAKER_00Exactly. And the frequency and intensity of the imaging also change. A standard annual mammogram might be supplemented with alternating breast MRIs.
SPEAKER_01Creating a much tighter surveillance net to catch any cellular abnormalities at like stage zero.
SPEAKER_00Right. And beyond heightened surveillance, specialists will discuss concrete risk reduction strategies. Well, this can involve targeted lifestyle modifications, the use of specific medications designed to lower cancer risk, or in some high-risk scenarios, discussions about preventative surgeries.
SPEAKER_01And the action plan also extends beyond the individual patient. A positive result triggers the recommendation to inform siblings, children, and extended family members so they can seek their own testing.
SPEAKER_00It's a family-wide effort.
SPEAKER_01But the value of this genetic data isn't just limited to prevention, is it? For patients who are already facing a cancer diagnosis, the genetic test results fundamentally guide the active treatment strategy.
SPEAKER_00Oh, absolutely. Oncology has moved far beyond a one-size-fits-all approach.
SPEAKER_01Yeah. The center provides extensive resources on the role of genetic testing in active breast cancer treatment.
SPEAKER_00Right, because knowing the precise genetic makeup of the tumor and the patient's underlying genetic vulnerabilities, well, it allows oncologists to select highly targeted therapies.
SPEAKER_01So they can identify which hormone-positive treatments will be most effective, or utilize specific drugs designed to exploit the very DNA repair glitch the BRCA mutation caused in the first place.
SPEAKER_00Exactly. The entire perspective shifts.
SPEAKER_01Because genetic testing is not a crystal ball showing a predetermined, unavoidable fate. It is the exact instruction manual to your body's specific vulnerabilities.
SPEAKER_00Yes. And having that manual allows you and your medical team to reinforce the weak points before they ever break.
SPEAKER_01It's amazing.
SPEAKER_00It represents a fundamental transformation in our relationship with human health. For generations, serious disease was viewed as a lottery, something that simply struck without warning.
SPEAKER_01But utilizing modern genetic screening, aided by the global clinical standards seen at facilities like the Onko Life Center, moves humanity into an era of anticipation and management.
SPEAKER_00You really do take the power back from the unknown. Knowing your genetic baseline provides an unprecedented level of control over your own longevity.
SPEAKER_01It gives you the tools to rewrite the ending of a story that your biology might have naturally drafted. But, you know, as this technology becomes more accessible, it leaves us with a lingering thought.
SPEAKER_00What's that?
SPEAKER_01If we are now fully capable of editing and anticipating our biological destiny through something as simple as a saliva test, at what point does knowing your genetic risk stop being just a personal medical choice and start becoming a standard ethical obligation to your family?